Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized placebo-controlled trial of AP31969 for atrial fibrillation rhythm control
NL-OMON59092Phase 2Recruiting
- Sponsor
- Acesion Pharma
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Atrial fibrillation (AFib) comparing AP31969 sulfate with Placebo (2 arms). Primary endpoint: AF burden from week 2 to week 12. Started Oct 2025; status: recruiting.
02
Drugs
AP31969
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON59092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59092.